Patents by Inventor Philip R. Tempest

Philip R. Tempest has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • High affinity humanized anti-tag-72 monoclonalantibodies
    Publication number: 20020193574
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Application
    Filed: October 31, 2001
    Publication date: December 19, 2002
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonalantibodies
    Publication number: 20020183497
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Application
    Filed: October 31, 2001
    Publication date: December 5, 2002
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-CEA monoclonal antibodies
    Publication number: 20020183495
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Application
    Filed: October 9, 2001
    Publication date: December 5, 2002
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-CEA monoclonal antibodies
    Publication number: 20020165387
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Application
    Filed: October 9, 2001
    Publication date: November 7, 2002
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-CEA monoclonal antibodies
    Patent number: 6417337
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Grant
    Filed: February 18, 1998
    Date of Patent: July 9, 2002
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonalantibodies
    Patent number: 6348581
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: February 18, 1998
    Date of Patent: February 19, 2002
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-CEA monoclonal antibodies
    Patent number: 6333405
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: December 25, 2001
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour